Tarsier Pharma proudly announces the appointment of Emilee Fulcher as Vice President of Clinical Affairs. In her new role, Emilee Fulcher will spearhead the execution of the TRS01 and TRS02 clinical programs towards the advancement of Tarsier Pharma's pipeline for Dazdotuftide (TRS), a novel multi-target drug for the treatment of ocular blinding diseases.
Who to call at Tarsier Pharma, and when
A new leader at Tarsier Pharma brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Tarsier Pharma raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Tarsier Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tarsier Pharma. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Tarsier Pharma
Location
Zichron Yaacov, Haifa District, Israel
About
Tarsier Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The company's most advanced candidate, TRS01 – an eye drop formulation of dazdotuftide, is entering its second phase 3 trial supported by a SPA agreement from the FDA.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tarsier Pharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.